EGFR T790M mutation testing within the osimertinib AURA Phase I study

Lung Cancer

Volumn 109, Issue , 2017, Pages 9-13

  Dearden, Simon ^a   Brown, Helen ^a   Jenkins, Suzanne ^a   Thress, Kenneth S ^a   Cantarini, Mireille ^a   Cole, Rebecca ^a   Ranson, Malcolm ^b   Jänne, Pasi A ^c  

^a ASTRAZENECA   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

EGFR genes; Non small cell lung cancer; Osimertinib; Protein kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OSIMERTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SANGER SEQUENCING; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; JAPAN; LABORATORY; LUNG TUMOR; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MULTICENTER STUDY; MUTATION; OBSERVER VARIATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REPRODUCIBILITY; UNITED STATES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; JAPAN; LABORATORIES; LUNG NEOPLASMS; MICROARRAY ANALYSIS; MUTATION; NEOPLASM STAGING; OBSERVER VARIATION; PATHOLOGY, MOLECULAR; PIPERAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 85018584267     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.04.011     Document Type: Article

References (35)

1. [1] NCCN, NCCN Clinical Practice Guidelines in Oncology NSCLC (version 7.2015). 2015 (Available at http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, Accessed on 16 July 2015.).
2. [2] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
3. [3] Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. [4] Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13306–13311.
5. [5] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
6. [6] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
7. [7] Sequist, L.V., Yang, J.C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31 (2013), 3327–3334.
8. [8] Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K.M., Peters, S., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25:Suppl. 3 (2014), iii27–iii39.
9. [9] Masters, G.A., Temin, S., Azzoli, C.G., Giaccone, G., Baker, S. Jr., Brahmer, J.R., et al. Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J. Clin. Oncol. 33 (2015), 3488–3515.
10. [10] Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005), 786–792.
11. [11] Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2, 2005, e73.
12. [12] Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
13. [13] Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
14. [14] Zhou, W., Ercan, D., Chen, L., Yun, C.H., Li, D., Capelletti, M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462 (2009), 1070–1074.
15. [15] Sequist, L.V., Soria, J.C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709.
16. [16] National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology NSCLC (version 4.2016). 2016 (Available at http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, Accessed on 4 April 2016).
17. [17] Jänne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
18. [18] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., McCormack, R., EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J. Clin. Pathol. 66 (2013), 79–89.
19. [19] Hagemann, I.S., Devarakonda, S., Lockwood, C.M., Spencer, D.H., Guebert, K., Bredemeyer, A.J., et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 121 (2015), 631–639.
20. [20] Karachaliou, N., Rosell, R., Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer (Auckl) 5 (2014), 73–79.
21. [21] Lee, H.J., Xu, X., Kim, H., Jin, Y., Sun, P., Kim, J.E., et al. Comparison of direct sequencing, PNA clamping-real time polymerase chain reaction, and pyrosequencing methods for the detection of EGFR mutations in non-small cell lung carcinoma and the correlation with clinical responses to EGFR tyrosine kinase inhibitor treatment. Korean J. Pathol. 47 (2013), 52–60.
22. [22] Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 15 (2013), 415–453.
23. [23] O'Donnell, P., Ferguson, J., Shyu, J., Current, R., Rehage, T., Tsai, J., et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer, 13, 2013, 210.
24. ® EGFR Mutation Test v2. 2015 (Available at http://molecular.roche.com/assays/Pages/cobasEGFRMutationTest.aspx, Accessed on 1 October 2015.).
25. [25] FDA Summary of Safety and Effectiveness Data (SSED), Premarket Approval (PMA) P120019, cobas EGFR Mutation Test v2. 2015 (Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120019S007, Accessed on 08 July 2016.).
26. [26] Yang, J.C.-H., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.-J., et al. Updated safety and efficacy from a Phase I study of AZD9291 in patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC). Ann. Oncol., 25(Suppl), 2014 Abstract 6874 (and Poster 449PD presented at ESMO).
27. [27] Benlloch, S., Botero, M.L., Beltran-Alamillo, J., Mayo, C., Gimenez-Capitan, A., de Aguirre, I., et al. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial. PLoS One, 9, 2014, e89518.
28. ® System. 2010 (Available at http://www.nature.com/app_notes/nmeth/2010/101304/full/an7545.html, Accessed on 1 October 2015.).
29. [29] Angulo, B., Conde, E., Suarez-Gauthier, A., Plaza, C., Martinez, R., Redondo, P., et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One, 7, 2012, e43842.
30. ® EGFR RGQ PCR kit instructions for use (handbook). 2013 (Available at http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120022c.pdf, Accessed on 1 October 2015.).
31. [31] de Bruin, E.C., McGranahan, N., Mitter, R., Salm, M., Wedge, D.C., Yates, L., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
32. [32] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
33. [33] Jiang, S.X., Yamashita, K., Yamamoto, M., Piao, C.J., Umezawa, A., Saegusa, M., et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int. J. Cancer 123 (2008), 2480–2486.
34. [34] Piotrowska, Z., Niederst, M.J., Karlovich, C.A., Wakelee, H.A., Neal, J.W., Mino-Kenudson, M., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5 (2015), 713–722.
35. [35] Thress, K.S., Brant, R., Carr, T.H., Dearden, S., Jenkins, S., Brown, H., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90 (2015), 509–515.